US 10238652
Compounds for treatment of cancer
granted A61KA61K31/4375A61K31/444
Quick answer
US patent 10238652 (Compounds for treatment of cancer) held by Curegenix, Inc. expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Curegenix, Inc.
- Grant date
- Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K31/4375, A61K31/444, A61K31/472, A61K31/4725